UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

October 17, 2018

Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses drug development in acute myeloid leukemia (AML).

October 16, 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.

October 16, 2018

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of carfilzomib (Kyprolis) in the treatment of patients with multiple myeloma.

October 12, 2018

A. Jo Chien, MD, discusses emerging agents and other developments in HER2-positive breast cancer.

October 12, 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses autologous stem cell transplant (ASCT) in multiple myeloma.

October 11, 2018

Michelle E. Melisko, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, reflects on the findings from the MINDACT trial in breast cancer.

October 11, 2018

Sandy Wong, MD, discusses emerging agents being explored for the treatment of patients with multiple myeloma in late relapse.

October 11, 2018

Laura J. Esserman, MD, MBA, discusses the goals of the I-SPY trials and their impact thus far on patients with high-risk early breast cancer.

October 10, 2018

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of minimal residual disease (MRD) status in the treatment of patients with chronic lymphocytic leukemia.

October 10, 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

October 10, 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses pathway blockade in breast cancer.

October 09, 2018

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the current state of CAR T-cell therapy in multiple myeloma.

October 09, 2018

Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the I-SPY 2 trial in breast cancer.

October 09, 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

October 05, 2018

Neil Shah, MD, PhD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses frontline treatment considerations for patients with chronic myeloid leukemia.

October 05, 2018

Lloyd Damon, MD, discusses novel therapies in acute myeloid leukemia, including FLT3 and IDH1/2 inhibitors.

October 05, 2018

Thomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.

October 05, 2018

Bita Fakhri, MD, MPH, shares her insight on the treatment of patients with newly diagnosed multiple myeloma.

October 04, 2018

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment duration in HER2-positive breast cancer.

October 02, 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in mantle cell lymphoma (MCL).